Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams, D.K., Chen, X.T., Tarby, C., Kaltenbach, R., Cai, Z.W., Tokarski, J.S., An, Y., Sack, J.S., Wautlet, B., Gullo-Brown, J., Henley, B.J., Jeyaseelan, R., Kellar, K., Manne, V., Trainor, G.L., Lombardo, L.J., Fargnoli, J., Borzilleri, R.M.(2010) Bioorg Med Chem Lett 20: 2998-3002
- PubMed: 20382527 
- DOI: https://doi.org/10.1016/j.bmcl.2010.01.042
- Primary Citation of Related Structures:  
3L8V - PubMed Abstract: 
Biarylamine-based inhibitors of Met kinase have been identified. Lead compounds demonstrate nanomolar potency in Met kinase biochemical assays and significant activity in the Met-driven GTL-16 human gastric carcinoma cell line. X-ray crystallography revealed that these compounds adopt a bioactive conformation, in the kinase domain, consistent with that previously seen with 2-pyridone-based Met kinase inhibitors. Compound 9b demonstrated potent in vivo antitumor activity in the GTL-16 human tumor xenograft model.
Organizational Affiliation: 
Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543-4000, USA. david.williams@bms.com